Nano-pulse stimulation (NPS) as a developing technology has been studied for minimally invasive, nonthermal local cancer elimination for more than a decade. Here we show that a single NPS treatment results in complete regression of the poorly immunogenic, metastatic 4T1-Luc mouse mammary carcinoma. Impressively, spontaneous distant organ metastases were largely prevented, even in those animals with incomplete tumor regression. All tumor-free mice were protected from secondary tumor cell challenge, demonstrating a vaccine-like effect. NPS treatment induced antitumor immunity, long-term memory T cells, destruction of tumor microenvironment and reversal of the massive increase of immune suppressor cells in the tumor microenvironment and blood. NPS-treated 4T1 cells exhibited release of damage-associated molecular patterns (DAMPs), including calreticulin, HMGB1 and ATP, and activated dendritic cells. Those findings suggest that NPS is a potent immunogenic cell death inducer that elicits antitumor immunity to prevent distant metastases in addition to local tumor eradication.
Breast cancer is the second leading cause of morbidity and mortality due to cancer in women. Metastatic mammary cancer presents considerable therapeutic challenges due to disease heterogeneity, absence of established therapeutic targets and poor prognosis. Despite great advances in therapeutic strategies, metastatic breast cancer has less effective treatments and there are no available cures. Surgery, hormonal therapy, radiation and cytotoxic chemotherapy are the standard treatment options. Commonly used chemotherapeutic agents such as anthracyclines, taxanes and cytophosphanes not only present significant toxicities but also promote aggressive resistant types of breast cancer that include high numbers of mammary cancer stem cells. 1 To address these issues, studies with a poorly immunogenic and metastatic 4T1 mouse orthotopic tumor model were undertaken. This model is one of the few breast cancer models that exhibit the capability to metastasize to the lungs, liver, brain and bones mimicking human advanced breast cancer. 2, 3 To treat these orthotopic 4T1 breast cancer tumors, we used nanosecond electric pulses, which have shown success in a variety of rat and mouse tumor models with several different cancer types. [4] [5] [6] [7] [8] [9] The technology to build generators that produce nanosecond-length electric pulses or nanosecond pulsed electric fields (nsPEFs) with short rise and fall times and high electric field strength, which is named here as nano-pulse stimulation (NPS), to treat cancer is a relatively recent advancement in pulsed power technology. 10, 11 NPS treatments of mammalian cells have been shown to permeabilize both plasma and organelle membranes, which allows entry of disruptive small ions, 12, 13 disturbs intracellular vesicles, 14, 15 and releases calcium from endoplasmic reticulum stores. 16, 17 Dissipation of the mitochondrial membrane potential has also been reported. 18 Effects of NPS on cells can induce stimulation, suppression, damage or death depending on the parameters of NPS and cell types or status. Previous research on NPS application has focused on local cancer ablation with various electric fields and pulse numbers. The mechanisms of cell death induced by NPS are caspase-dependent or -independent apoptosis 19 and necrosis, 20 most likely regulated necrosis defined as parthanatos. 21 Localized NPS delivery has demonstrated complete local tumor remission without recurrence in an in vivo melanoma mouse model, 9 and in mouse and a worse prognosis. Novel effective therapeutic strategies for metastatic eradication/control are an unmet urgent medical need for patient survival and an improved quality of life. NPS ablation as a new developing technology has not been extensively studied for breast cancer. Only one study has been reported to treat xenograft human breast cancer in an immunodeficient mouse model. 7 However, most recent work from the laboratories of Beebe 8 and Nuccitelli 5 has indicated that immune response induced by NPS ablation may be involved in the tumor regression and protection from second tumor challenge.
In this study, we employ an orthotopic mouse metastatic breast cancer model to test if NPS ablation could effectively ablate primary cancer and more importantly to explore if antitumor immunity is induced by NPS tumor ablation and help control distant metastasis. We have found that mouse breast tumors treated with NPS can significantly prolong survival with complete tumor regression and prevent metastases. Long-term antitumor memory was induced to reject second tumor challenge. NPS local tumor treatment both disrupts the immune-suppressive microenvironment and induces a potent antitumor specific immunity involving cytotoxic T cells. In vitro and in vivo studies support that NPS treatment is a potent new immunogenic cell death (ICD) inducer to elicit antitumor immunity in situ. (100 units/ml penicillin and 100 lg/ml streptomycin). 4T1 cells and 4T1-luc cells with passage number 2-7 were thawed for expansion. Cells with passage number 9-30 were used in the described experiments. 
Material and Methods

Cell lines
Reagents and antibodies
Mice and tumor models
Female Balb/c mice (8-10 weeks of age) were purchased from Jackson Laboratory or Harlan Laboratories, housed and maintained in the ODU AAALAC approved animal facility. Mice were injected subcutaneously with 1 3 10 6 4T1-Luc 3 or 4T1 cells in 50 lL Dulbecco's phosphate buffered saline with calcium and magnesium (DPBS) in the posterior part of the mammary fat pad. The size of primary tumor was assessed by calipers and the Xenogen IVIS Spectrum system (Caliper Life Sciences) as indicated below. Mice were weighed before and post-treatment and twice weekly. Mice were euthanized at the end of the follow-up period or at specified time points described in experimental designs or when they met the criteria described at experimental endpoints in the approved IACUC protocol.
In vitro and in vivo NPS delivery
In vitro NPS treatment for cancer cells was described in our previous publication. 22 For in vivo NPS tumor ablation, NPS were delivered to tumor tissue using a five-needle electrode array, 8 taken with needle electrodes to be sure needles are completely surrounding and only within the tumor mass during treatment. The pulse parameters were pulse duration 100 ns, frequency 1-2 Hz, applied electric fields 50 kV/cm (with a range of 46-54 kV/cm) and pulse number 300, 600 or 1000 depending on experimental designs. Hair was thoroughly removed by using Nair treatment following shaving, and electrodes were covered with either K-Y jelly or ultrasound gel.
Cell viability assay
WST-1 viability assays were described in our previous publication. 22 As luciferase expression in 4T1-luc cells is stable during in vitro culture and not affected by NPS, 23 sometimes total luciferase expression was measured and calculated for cell viability. In this case, after 18 hr incubation, total luciferase expression of control cells without NPS treatment was seen as 100% cell viable, and viability of cells treated with NPS was determined by a formula: Viability of treated cells 5 luciferase expression of treated cells/luciferase expression of control cells 3 100%.
Tumor volume measurement
Tumors were measured twice a week using a digital caliper. Tumor volume was determined using the following formula:
, where a is the longest diameter and b is the shortest diameter perpendicular to a. 24 The mice were monitored for tumor growth or regression for the duration of the experiment, or until primary tumor volumes reached 1,500 mm 3 .
In vivo or ex vivo imaging
At various times or twice a week, animals were administrated intraperitoneally with D-luciferin 150 mg/gram body weight in PBS (stock solution 15 mg/ml). After 10-15 min, animals were imaged under anesthesia with 2.5% isofluorane in a Xenogen IVIS 100 spectrum. At experimental endpoints, luciferin-injected animals were euthanized and organs were removed and imaged within 30 min. Luminescence is expressed as photons/sec/ROI (region of interest) minus background luminescence for a similarly sized region.
Isolation of peripheral blood monocytes (PBMCs), splenocytes and tumor infiltrate cells
Blood was collected by tail vein bleeding or cardiac puncture. Blood was spun down, supernatant was removed then mixed with 103 ACK lysis buffer (1 ml/0.1 ml volume of blood) at room temperature in the dark for 10 min. Cells were washed with DPBS twice and prepared for culture or staining. Spleens were cut into pieces and minced in 40-lm nylon cell strainers. As mentioned above, red blood cells were lysed by mixing with 2-10 ml ACK lysis buffer, depending on the size of spleens.
Tumors were minced into thin pieces and were dissociated in collagenase I (200 U/ml), DNase I (200 U/mL; SigmaAldrich), in complete culture medium for 1 hr at 378C. Dissociated tumor tissues were then passed through a 40-lm nylon cell strainer to obtain a single-cell suspension.
Ex vivo splenocyte restimulation with anti-CD3 Ab or tumor lysate
One day prior to incubation, low-endotoxin/azide-free LEAF anti-CD3 Ab (0.5 mg/ml in DPBS) was coated into a 24-well plate and incubated at 48C. Anti-CD3-coated wells were washed with DPBS three times before cells were added. Splenocytes (2 million/ml) 1 ml per well were incubated with media, tumor lysate (10 mg/ml) or plate-bound anti-CD3 Ab in a 24-well plate. For intracellular cytokine staining, cells were incubated for 6 hr and monensin added for the final 4 hr. For IFN-g production, cells were incubated for 24 hr and supernatants were collected for ELISA assay.
Determination of cell surface CRT, release of ATP and HMGB1 from NPS-treated breast cancer cells 0.1 ml 4T1 cells (5 3 10 6 /ml) in complete media were loaded in a 1-mm-gap cuvette and treated with NPS with 60 ns, 50 kV/cm, 1 Hz and 60 pulses which was determined by viability assay with >90% cell death. Cells then were placed in a 6-well plate for 4 hr or 20 hr. Cells with media but no NPS treatment served as negative control and a known ICD inducer, mitoxantrone (1 mM) was added to cells as a positive control. Cell surface-exposed CRT was measured by flow cytometry (FACSAria). Extracellular ATP concentrations were quantified by the luciferase/luciferin-based ATP determination Kit (A22066, Thermo-Fisher). Amount of HMGB1 in the supernatant was determined by HMGB1 ELISA Kit (MBS722248, MyBioSource).
Preparation and stimulation of bone marrow-derived DCs (BMDCs)
BMDCs were prepared from harvested bone marrow cells by 8 day incubation in the presence of 20 ng/ml GM-CSF (R&D). BMDCs were stimulated with media as a control, LPS (5 mg/ml) or CPG 1668 (5 mM) as positive controls, NPS-treated 4T1 cells or directly treated with low dose of NPS (5-10 pulses, 60 ns, 50 kV/cm and 1 Hz). Cells were incubated at 378C with 5% CO 2 for 24-48 hr then analyzed cell surface activation markers (MHC-II, CD40 and CD86) by flow cytometry.
Flow cytometry
For the cell surface staining, 1-2 million PBMCs, splenocytes or tumor infiltrate cells in 100 mL complete media or FACS buffer (2% FBS DPBS) were added with antibody mixture and incubated at room temperature for 30 min. Cells then were washed with 2 ml FACS buffer twice and resuspended in 0.5 ml FACS buffer with 2.5% paraformaldehyde (PFA) for flow cytometric analysis by FACSAria (BD Biosciences).
For intracellular staining, cells were prepared by preincubation with purified anti-CD16/32 (Fc block), followed by surface labeling of cells with anti-CD4 FITC, anti-CD8 PerCP Cancer Therapy and Prevention Guo et al. or anti-CD25 APC, followed by intracellular staining using mAbs anti-IL-17A PE-Cy7 and anti-IFN-g PE after fixation and permeabilization with fixation and permeabilization buffer. In case of PE antimouse/rat/human FOXP3 staining, True-Nuclear TM Transcription Factor Buffer Set was used for fixation and permeabilization. Samples were analyzed on a flow cytometer (FACSAria, BD Biosciences).
Statistical analysis
All values are reported as the mean 6 standard deviation (SD 
Results
Complete tumor regression resulting from single treatment of NPS
There are no data or previous studies of cytotoxicity of NPS to 4T1 or 4T1-luc breast cancer cells in vitro or tumors in vivo. For in vitro studies, pulse number-dependent cytotoxicity of NPS for 4T1-luc cells are shown in Supporting Information, Figure S1 . LD50 or LD99 for NPS with 60 ns, 1 Hz, 50 kV/cm is about 12 pulses and 45 pulses, respectively. For in vivo studies, we used the same pulser as in previous studies. 4, 8 We treated 4T1-luc tumors with 100 ns, 1-2 Hz, 50
kV/cm and a range from 300 to 1,000 pulses for breast cancer elimination. With a five-needle electrode previously used 4, 8 at high number of NPS pulses (1,000 pulses), a single treatment eradicated 100% of cancer in mice (4/4) without recurrence for 7 weeks when the study was terminated (Fig. 1d ). In contrast, lower numbers of NPS pulses (300 pulses) only eliminated 33% of 4T1-luc tumors in mice (2/6, Fig. 1c ). Because of scab formation, the caliper measurements were not an adequate indication of real tumor regression within 10 days after treatment, especially for 1,000 pulse treatment group In additional studies, we used a two-needle electrode or a two-plate suction electrode with the same 5 mm gap. However, no complete tumor regressions (0/7, Supporting Information, Fig. S2 ) were achieved by using the two-needle electrode at 600 pulses or 23 600 pulses by applying electrodes in successive perpendicular applications in the same treatment session. With the suction electrode, 50% (7/14) of tumors completely regressed by a single treatment with 600 pulses (Figs. 2a and 2b) . Multiple tumor treatment sessions were not carried out in these studies. Similar to previous studies treating ectopic tumors, scabs form after treatment. 6 This scab is resolved within 2 weeks.
Prevention of distant metastases from incomplete local tumor ablation after NPS treatment
As the 4T1-luc tumor model is metastatic, we were interested in determining levels of distant metastasis in control and incompletely regressed tumors; therefore, mouse tumors were treated with intermediate pulse numbers of NPS pulses (600 pulses), 50% of animals were tumor free by both caliper measurement and in vivo imaging, and 50% (7/14) of animals were incompletely treated with tumor regrowth occurring 2 weeks post-treatment (Figs. 2a and 2b) . Median survival significantly increased 25 days in the incompletely treated group compared to control animals (Fig. 2b) . Noticeably, tumors were unmeasurable or greatly shrank in two animals at the second week post-treatment and regrew, but remarkably slowly (Fig. 2a) . The tumor doubling-times of those two animals were 50% longer than other NPS-treated or control animals ( Supporting Information, Fig. S3 ).
We analyzed control and treated tumors of similar sizes (4 weeks for controls and 7 weeks or longer for NPS-treated tumors). Distant metastases were found in liver, lung and/or spleen in 82% (9/11) of control mice (Fig. 2c) . Strikingly, six of seven mice (86%) with incomplete tumor regression exhibited no detectable metastases in liver, lung or spleen by luminescent ex vivo imaging of isolated organs (Fig. 2d) . Again, comparisons of metastasis between control and treated tumors were made when both tumor sizes were equivalent. We hypothesized that prevention of spontaneous metastasis was due to antitumor immunity induced after NPS treatment itself. So next we determined if long-term antitumor immune memory was present and characterized local and systemic immune response after NPS treatment.
Potent antitumor memory response in tumor-free mice after NPS treatment
To examine if antitumor immune memory was established following successful NPS treatment, a total of 11 tumor-free mice were challenged with 0.5 million 4T1-luc cells in the opposite mammary gland at least 7 weeks after the initial treatment. All mice (11/11) rejected secondary tumor growth (Fig. 3) . As a matter of fact, red, soft inflammatory spots were observed at the injection sites in the majority of tumorfree mice one week after challenge, with complete resolution within 2-3 weeks. On the contrary, all nine na€ ıve, agematched control mice grew large tumors (Fig. 3 ) and had to be euthanized in 5-6 weeks postinjection.
Similar to the diminution of metastasis, protection from challenge injections suggested an immune memory response. Therefore, we analyzed phenotypes of CD41 and CD81 Tcells for markers of effector and central memory cells in blood and spleen of control and treated mice. Compared to control mice, both effector and central memory CD81 and CD41 T cells in the spleen and blood were significantly depressed in tumor-bearing mice. However, both of CD41 and CD81 T memory cells in the blood or spleen of treated, tumor-free mice were recovered or surpassed levels of control mice, especially central memory CD41 and CD81 T cells. Memory T cells in spleens were greatly increased in the tumor-free mice compared to na€ ıve control mice with CD41 (3.61% vs 0.62%) and CD81 T-cells (1.38% vs 0.2%) and compared to tumor-bearing mice with CD41 (3.61% vs 0.22%) and CD81 (1.38% vs 0.06%) T-cells (Fig. 4a and Supporting Information, Fig. S4 ). After restimulation with anti-CD3 antibody for 6 hr, IFNg producing CD41 (0.242%) and CD81 T cells (0.364%) from spleens of tumor-free mice were significantly increased whereas IFN-g producing T cells from tumor-bearing mice (0.029% for CD41 and 0.031% for CD81 T cells) were largely decreased in contrast to na€ ıve control mice (0.135% for CD41 and 0.116% for CD81 T cells) (Figs. 4d-e) . The significant decrease of cytotoxic T cells in tumor-bearing mice can be explained with immune suppressive status evidenced in the following studies. Furthermore, tumor specific IFN-g production after splenocytes co-culture with tumor lysate was increased as well (Fig. 4f) . The significantly high amount of IFN-g was released from splenocytes of tumorfree mice (75.9 pg/ml vs 28.5 pg/ml in the media control) in response to tumor antigens for 24 hr but not in the na€ ıve mice (31.5 pg/ml) or tumor mice (21.1 pg/ml). Reversal of suppressive systemic immune environments after successful NPS treatment 4T1-luc breast cancer had a profound impact on hematopoietic and lymphatic systems of animals, such as splenomegaly ( Supporting Information, Fig. S5) , extremely high leukocytosis ( Supporting Information, Fig. S5 ), myeloid derived suppressor cells (MDSCs) (Fig. 5d) and IL-17 secreting cells ( Supporting  Information, Fig. S6 ). However, successful NPS treatment reversed those tumor derived immune suppressive changes. As shown in Figure 5a , 78.8% of CD41 T cells were CD251 Foxp31 Treg cells in the blood of the tumor-bearing mice. In contrast, only 11.0% or 10.2% of CD41 T cells were Treg cells in the tumor-free mice or control naive mice, respectively (Figs. 5ac). Changes were examined for MDSCs as well. Compared to naive mice (6.4%) or tumor-free mice (4.5%), 13.7-fold or 19.5-fold increase of blood CD11b 1 Gr11 MDSCs in tumor-bearing mice (87.8%) were measured by flow cytometry (Figs. 5df) . Moreover, the level of MDSCs was correlated to tumor burden, which indicated success or failure of NPS treatment. At post-treatment Day 7, animals with regressing tumor exhibited only 14.0% MDSCs in the blood. That was much lower than 37.6% MDSCs in the blood of animals with growing tumor or treatment failure (Figs. 5e and 5f ). Noticeably, a significant population of Th17 cells was discovered in the spleens of tumor-bearing mice but not in the control or tumor-free mice ( Supporting Information, Fig. S6 ).
Destruction of suppressive tumor microenvironments and activation of antigen-presenting cells following NPS treatment
Myeloid-derived suppressor cells (MDSCs) are known to accumulate in 4T1 mammary carcinoma bearing mice and present a barrier to the success of adoptive immunotherapy by suppressing T-cell immunity. 25, 26 . In our studies, interestingly, MDSCs in tumor were significantly decreased 2 days after treatment with NPS, from 23.6% of total cells in control tumor to 5.4% in NPS-treated tumor (Fig. 6a) . On the other hand, tumor associated F4/80 1 CD11c1 macrophagedendritic cells (M-DCs) 27 increased from 2.6% in control tumors to 14.4% in treated tumors (Fig. 6b) . Not only did the number of M-DCs go up but also one of activating markers CD40 was up-regulated. 83.1% of M-DCs were CD40 positive in treated tumors but only 50.1% of M-DCs in control tumor (Fig. 6c) . At post-treatment Day 7, immune suppressive Tregs decreased from 14.8% of CD41 cells in control tumor to 4.7% of CD41 cells in treated tumor (Fig.  6d and Supporting Information, Fig. S7 ).
These data demonstrate that NPS treatment induces immune responses by reversing the suppression of the tumor microenvironment, initiating antitumor cytotoxic T cells and promoting effector and central memory T-cells. However, it is not clear how these immune responses are instructed. To further understand how NPS-induced tumor elimination activates DCs, we assessed whether NPS treated cells activate DCs in vitro and determined its possible mechanism. MHC-II (IA/IE) and co-stimulatory molecules, CD86 and CD40 were upregulated 2 days after DCs cocultured with NPS treated 4T1 cells (Supporting Information, Fig. S8D ) under LD90 condition (Supporting Information, Fig. S1 ). Those results are quite consistent with our in vivo findings and support the hypothesis that tumor death by NPS activates antigen-presenting cells. Moreover, DCs were activated after treatment with nonlethal dose of NPS as well. As seen in Supporting Information, Figure S9 , the 
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expression of all three markers-IA/IE, CD86 and CD40-on DCs were increased.
Release of damage-associated molecular patterns (DAMPs) from cell death caused by NPS It is well characterized that release of several DAMPs from known chemotherapeutic drug induced cancer cell death can initiate antitumor immunity. 
Discussion
The most striking finding in this study is potent antitumor immunity induced by local NPS tumor elimination. After NPS treatment, all 11 tumor-free mice (100%) rejected a second tumor challenge injection. This is consistent with the vaccine-like effect in previous studies with the orthotopic N1-S1 HCC model where following tumor elimination for 7 weeks, all tumor-free rats were protected (21/21) from orthotopic challenge injections of the same tumor line. 8 Yet more impressive, for tumors that exhibited partial responses, NPS treatment resulted in a significant reduction in spontaneous distant organ metastases compared to untreated, control tumors of similar size. Furthermore, antitumor-specific IFN-g production was increased in the NPS-treated tumor-free mice. Consistent with challenge data and attenuation of metastasis, both CD41 effector memory T-cells and CD81 effector and central memory T-cells were significantly increased in tumor-free animals compared to naive mice or tumor-bearing mice. In addition, significant numbers of cytotoxic CD41 and CD81 T cells were detected in splenocytes from tumor-free mice in response to anti-CD3 stimulation.
Another impressive result of effective treatment with NPS is the reversal of immune suppressive tumor microenvironment in the 4T1-luc model. The tumor microenvironment is recognized to play multiple roles in tumor progression, drug resistance, immune suppression and angiogenesis and metastasis. 30, 31 Necessarily, this dysfunctional cancer niche is now established as a therapeutic target. 32, 33 It is well known that 4T1/4T1-luc breast cancer is a poorly immunogenic and highly spontaneous metastatic cancer model 3, 34 and very closely mimics human advanced breast cancer. 2, 3 The immunological characteristics of tumor-bearing mice were present here, including massive MDSCs and Tregs in the blood and tumor microenvironment, attenuation of cytotoxic T-cells and anergy to immune stimulation or tumor antigens. All these 4T1 characteristics provide evidence for the aggression of this mammary carcinoma model. Additional evidence for the highly metastatic potential in the 4T1 model is the powerful presence of MDSCs in the tumor microenvironment, which have been shown to be important for angiogenesis, 35 a co-cancer hallmark with invasion and metastasis. 36 The impressive power for NPS rapidly to silence the suppressive immune microenvironment within 2 days after treatment likely plays a critical role in the diminution of angiogenesis and metastasis after treatment. A critical question is how elimination of local tumor by NPS consequently induces a potent antitumor immune response in this poorly immunogenic cancer model? Our hypothesis is that two major mechanisms are involved in the induction of antitumor immunity following NPS therapy: (1) tumor microenvironment destruction, which was discussed above and (2) ICD induction. ICD markers, including CRT, ATP or HMGB1, were released from NPS-treated 4T1 cells. Bone marrow derived dendritic cells were activated and upregulated MHC-II, co-stimulatory molecules CD86 and CD40 after co-culture with NPS-treated 4T1 cells. The recruitment of DCs and CD40 upregulation was found in tumor after NPS tumor ablation as well. Another mechanism that may also participate is direct activation of antigen-presenting cells by NPS. We have found that DCs can be activated (Supporting Information, Fig. S9 ) with nonlethal doses of NPS, which likely occurs at peripheral area of tumor or in the normal tissue surrounding tumor where electric fields are below lethal levels. Taken all together, first, NPS induces regulated cancer cell death, which releases DAMPs and tumor-associated antigens. Meanwhile immune suppressive tumor microenvironment is destroyed. Second, DCs are recruited into tumor tissue, activated by DAMPs and loaded with tumorassociated antigens, and/or DCs residing at peripheral tumor are activated by direct NPS. Third, DCs migrate into lymphoid tissue and present antigens to T helper cells. Finally, effector cytotoxic and memory T cells are generated to eliminate residual cancer cells, micrometastasis and prevent reoccurrence. To validate those dynamic immune responses, more data are needed to gain insights into what exactly happen after NPS tumor ablation and support this hypothesis.
Antitumor immunity has been shown in other types of local tumor ablation therapies, but it is often modest and only effective if used in combination with systemic/local immunotherapy. Whether antitumor immunity or abscopal effect induced with cryoablation has been achieved is controversial. 37 Hyperthermia by radio frequency ablation (RFA) has been utilized for local tumor ablation in clinics for decades. Though RFA ablation for hepatocellular carcinoma or metastatic liver cancer was reported to induce antitumor immunity, 38, 39 other help, such as the addition of anti-PD-1 antibodies are needed to achieve prolonged survival. 40 However, Manjili's group showed that RFA alone failed to induce anti-tumor specific immune responses in a 4T1 mouse breast cancer model, whereas the combination with local IL-7 and IL-15 injection was necessary to elicit effective immune responses. 41 Gameiro et al. 42 demonstrated that systemic vaccine enhanced antitumor immunity of RFA tumor ablation for local and distal tumor regression. Irreversible electroporation (IRE) as a minimally invasive approach for tumor ablation is another local therapy currently being tested in clinics. 43 Whether IRE tumor ablation could induce antitumor immunity is inconclusive. One study showed that no infiltration of immune cells was found following IRE tumor ablation. 44 The fact that distant metastasis and local recurrence are major failures following IRE treatment in local advanced pancreatic cancer 45 suggests IRE alone either cannot induce antitumor immunity or is not strong enough to eradicate residual cancer or distant micrometastasis. Radiation is another major local cancer therapy that has been used for half a century. The abscopal effect, which was proposed as immune response following radiotherapy, has been found in clinics, but only in rare cases. 46 Recently, immune checkpoint inhibitors have shown significant efficacy in several types of metastatic cancer. 47 An abscopal effect has been reported in a melanoma patient treated with immune checkpoint inhibitors and concurrent radiotherapy. 48 An idea that the combination of these two modalities could improve outcomes including abscopal effect is being investigated in clinical trials. 49 To evaluate the abscopal effect of NPS, a study has been initiated and preliminary results indicate NPS local tumor ablation would lead to the complete regression or growth inhibition of distant untreated tumors. Our findings taken together with those data suggest clinical potential of NPS in the treatment of metastatic breast cancer, especially micrometastasis. To address this feasibility, we are investigating if antitumor immunity could be induced following human breast cancer treated with NPS.
Summary
Our study has demonstrated that local tumor eradication with NPS can induce potent antitumor immune response to reject tumor challenge and substantially reduce spontaneous distant organ metastases in a poorly immunogenic and highly metastatic breast cancer model. Three different mechanisms, including destruction of tumor microenvironment, induction of ICD and activation of antigen presenting cells, are, at least in part, involved in antitumor immunity elicited by NPS tumor ablation. A novel concept of NPS tumor deathimmunotherapeutic strategy is proposed here to treat advanced cancer more effectively. This ablation induced potent immunity, if confirmed in humans, should be particularly beneficial for breast cancer patients with high metastasis risk and/or evidence of micrometastasis. This unique local ablation of the tumor microenvironment plus induced systemic immunity may overcome those primary/recurrent cases resistant to current standards of care or targeted therapy.
